FDA hands Avanir a setback on Zenvia

Avanir Pharmaceuticals announced today that the FDA issued an approvable letter for Zenvia for involuntary emotional expression disorder but will require additional data before it can be formally approved. Avanir said that it would need to meet with the FDA to determine exactly what the agency is seeking, and even then isn't certain "that it will choose to continue with the development of Zenvia as previously planned." The San Diego-based biotech markets FazaClo for schizophrenia. Avanir stock plunged 40 percent on the news of the FDA's decision.

- here's the report on Avanir from TheStreet.com
- and here's the release on the FDA's letter

Suggested Articles

Tango Therapeutics is ditching its digs in Kendall Square to move into a new building in Boston’s Fenway neighborhood. Third Rock is coming, too.

UPenn scientists found blocking the Wnt/beta-catenin pathway in endothelial cells made chemotherapy more effective in mouse models of glioblastoma.

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.